The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final analysis of the phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, K-RAS wild-type (WT), metastatic colorectal carcinoma (mCRC): The NCIC Clinical Trials Group and AGITG CO.20 trial.
Lillian L. Siu
Research Funding - Bristol-Myers Squibb
Jeremy David Shapiro
Consultant or Advisory Role - Merck Serono
Derek J. Jonker
No relevant relationships to disclose
Christos Stelios Karapetis
Consultant or Advisory Role - Merck Serono
John Raymond Zalcberg
Consultant or Advisory Role - Merck Serono
Research Funding - Bristol-Myers Squibb; Merck Serono
Other Remuneration - Merck Serono
John Simes
Research Funding - Bristol-Myers Squibb
Felix Couture
No relevant relationships to disclose
Malcolm J. Moore
No relevant relationships to disclose
Timothy Jay Price
Consultant or Advisory Role - Merck Serono (U)
Jehan Siddiqui
No relevant relationships to disclose
Louise M. Nott
No relevant relationships to disclose
Danielle Charpentier
No relevant relationships to disclose
Winston S. Liauw
No relevant relationships to disclose
Michael B. Sawyer
Honoraria - Bristol-Myers Squibb
Other Remuneration - Bristol-Myers Squibb
Michael Jefford
No relevant relationships to disclose
Nadine M Magoski
No relevant relationships to disclose
Andrew Mark Haydon
No relevant relationships to disclose
Ian B. Walters
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Dongsheng Tu
No relevant relationships to disclose
Christopher J. O'Callaghan
No relevant relationships to disclose